VCEL
Vericel Corp
$36.30
+1.71%
$1.8B
No data for this timeframe.
Vol
Market Cap$1.8B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders7 funds
Inst. Value$288.2M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 10S
Insider Net $-$1.9M
SEC Reports8
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. MI·CIK 0000887359·Prev Close $35.69
Recent Activity
Jun 2, 2026
SEC
Jonathan M. Hopper, an officer of Vericel Corp, filed a Form 144 on June 2, 2026, indicating intent to sell 4,375 shares
144 — Impact 2/10
Jun 2, 2026
Insider
Hopper Jonathan Mark sold 4,375 shares
Chief Medical Officer @ $35.00 ($153.1K)
Jun 2, 2026
Insider
Hopper Jonathan Mark sold 4,375 shares
Chief Medical Officer @ $16.66 ($72.9K)
Jun 2, 2026
Insider
Hopper Jonathan Mark sold 4,375 shares
Chief Medical Officer @ $0.00 ($0.00)
May 15, 2026
SEC
Vericel Corp insiders sold ~$459K in open-market transactions over the past week, representing a trivial 0.027% of the $
CLUSTER — Impact 2/10
May 7, 2026
SEC
Vericel reported Q1 2026 total revenue of $68.4M (+30% YoY), beating the $63.6M consensus, and a GAAP net loss of $0.12/
8-K — Impact 7/10
Inst.
BANK OF AMERICA CORP — ADD
918,010 shares ($33.1M)
Inst.
MORGAN STANLEY — ADD
697,723 shares ($25.1M)
Price Targets
$55.43
+52.7% upside
Strong Buy
Current $36.30
Low $42.00
Median $55.00
High $70.00
7 analysts
$42.00
$70.00
Analyst Ratings
5Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Feb 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 18, 2025 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.04 ▼ -333.3% | $-0.06 — $-0.01 | -250% YoY | 4 |
| Next Q | $0.09 ▲ +18.6% | $0.04 — $0.12 | -15% YoY | 4 |
| Current FY | $0.45 ▲ +4.7% | $0.34 — $0.56 | 41% YoY | 5 |
| Next FY | $0.85 ▲ +5.8% | $0.73 — $1.02 | 89% YoY | 5 |
Latest Reports
NEUTRAL
144
2/10
Jonathan M. Hopper, an officer of Vericel Corp, filed a Form 144 on June 2, 2026, indicating intent to sell 4,375 shares
Jun 2, 2026
NEUTRAL
CLUSTER
2/10
Vericel Corp insiders sold ~$459K in open-market transactions over the past week, representing a trivial 0.027% of the $
May 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $129.1M | — |
| FMR LLC | $78.2M | — |
| BANK OF AMERICA CORP | $33.1M | ADD |
| MORGAN STANLEY | $25.1M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $17.2M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Hopper Jonathan | SELL | $153.1K |
| Jun 2, 2026 | Hopper Jonathan | M | $72.9K |
| Jun 2, 2026 | Hopper Jonathan | M | $0.00 |
| May 13, 2026 | MCLAUGHLIN KEVIN | M | $9.2K |
| May 13, 2026 | MCLAUGHLIN KEVIN | SELL | $114.9K |
7 institutional holders with $288.2M total value (8,003,456 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, BANK. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,584,006 | $129.1M | 44.8% | — |
| 2 | FMR LLC | 2,172,985 | $78.2M | 27.2% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 918,010 | $33.1M | 11.5% | ADD +74.0% |
| 4 | MORGAN STANLEY | 697,723 | $25.1M | 8.7% | ADD +26.5% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 478,290 | $17.2M | 6.0% | NEW |
| 6 | WELLS FARGO & COMPANY/MN | 112,944 | $4.1M | 1.4% | — |
| 7 | TWO SIGMA INVESTMENTS, LP | 39,498 | $1.4M | 0.5% | TRIM -25.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 527,568 | 918,010 | +74.0% | $33.1M | 2025-Q4 |
| MORGAN STANLEY | ADD | 551,761 | 697,723 | +26.5% | $25.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 52,713 | 39,498 | -25.1% | $1.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 52,713 | — | $1.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 47,500 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | ADD | 117,719 | 197,581 | +67.8% | $8.8M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 89,500 | 47,500 | -46.9% | $2.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 32,479 | 22,396 | -31.0% | $999.3K | 2025-Q1 |
| UBS Group AG | ADD | 68,563 | 117,719 | +71.7% | $6.5M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 119,557 | 32,479 | -72.8% | $1.8M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 434,206 | — | $18.3M | 2024-Q3 |
12 unique insiders with 10 transactions. Net insider value: -$1.9M ($0.00 bought, $1.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Hopper Jonathan Mark | Chief Medical Officer | SELL | 4,375 | $35.00 | $153.1K |
| Jun 2, 2026 | Hopper Jonathan Mark | Chief Medical Officer | M | 4,375 | $16.66 | $72.9K |
| Jun 2, 2026 | Hopper Jonathan Mark | Chief Medical Officer | M | 4,375 | $0.00 | $0.00 |
| May 13, 2026 | MCLAUGHLIN KEVIN F | Director | M | 3,500 | $2.63 | $9.2K |
| May 13, 2026 | MCLAUGHLIN KEVIN F | Director | SELL | 3,500 | $32.83 | $114.9K |
| May 13, 2026 | MCLAUGHLIN KEVIN F | Director | M | 3,500 | $0.00 | $0.00 |
| May 11, 2026 | Wotton Paul K | Director | SELL | 2,500 | $33.05 | $82.6K |
| May 7, 2026 | Mara Joseph Anthony Jr | Chief Financial Officer | SELL | 5,000 | $40.50 | $202.5K |
| May 7, 2026 | SIEGAL JONATHAN | Principal Accounting Officer | SELL | 1,422 | $40.50 | $57.6K |
| May 6, 2026 | SIEGAL JONATHAN | Principal Accounting Officer | SELL | 3,433 | $38.00 | $130.5K |
| Apr 29, 2026 | WRIGHT LISA | Director | A | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | WRIGHT LISA | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | WRIGHT LISA | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | ZERBE ROBERT L MD | Director | A | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | ZERBE ROBERT L MD | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Rubino Alan L | Director | A | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Rubino Alan L | Director | A | 8,000 | $0.00 | $0.00 |
| Apr 29, 2026 | ZERBE ROBERT L MD | Director | A | 8,000 | $0.00 | $0.00 |
| Apr 29, 2026 | Rubino Alan L | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Wotton Paul K | Director | A | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Wotton Paul K | Director | A | 8,000 | $0.00 | $0.00 |
| Apr 29, 2026 | Wotton Paul K | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Wotton Paul K | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Hagen Heidi | Director | A | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Hagen Heidi | Director | A | 8,000 | $0.00 | $0.00 |
| Apr 29, 2026 | WRIGHT LISA | Director | A | 8,000 | $0.00 | $0.00 |
| Apr 29, 2026 | ZERBE ROBERT L MD | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Rubino Alan L | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Hagen Heidi | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | Hagen Heidi | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | MCLAUGHLIN KEVIN F | Director | A | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | MCLAUGHLIN KEVIN F | Director | A | 8,000 | $0.00 | $0.00 |
| Apr 29, 2026 | MCLAUGHLIN KEVIN F | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 29, 2026 | MCLAUGHLIN KEVIN F | Director | M | 3,200 | $0.00 | $0.00 |
| Apr 2, 2026 | Hopper Jonathan Mark | Chief Medical Officer | M | 3,472 | $10.95 | $38.0K |
| Apr 2, 2026 | Hopper Jonathan Mark | Chief Medical Officer | SELL | 3,472 | $35.00 | $121.5K |
| Apr 2, 2026 | Hopper Jonathan Mark | Chief Medical Officer | M | 3,472 | $0.00 | $0.00 |
| Mar 25, 2026 | Rubino Alan L | Director | M | 15,000 | $0.00 | $0.00 |
| Mar 25, 2026 | Rubino Alan L | Director | M | 15,000 | $2.76 | $41.4K |
| Mar 23, 2026 | Hagen Heidi | Director | M | 15,000 | $2.76 | $41.4K |
| Mar 23, 2026 | Hagen Heidi | Director | M | 15,000 | $0.00 | $0.00 |
| Mar 23, 2026 | Hagen Heidi | Director | SELL | 15,000 | $32.41 | $486.1K |
| Mar 2, 2026 | Halpin Michael | Chief Operating Officer | SELL | 10,305 | $35.30 | $363.8K |
| Mar 2, 2026 | Flynn Sean C. | Chief Legal Officer | SELL | 6,421 | $34.75 | $223.1K |
| Mar 2, 2026 | Flynn Sean C. | Chief Legal Officer | M | 15,000 | $0.00 | $0.00 |
| Feb 24, 2026 | SIEGAL JONATHAN | Principal Accounting Officer | M | 1,540 | $0.00 | $0.00 |
| Feb 24, 2026 | SIEGAL JONATHAN | Principal Accounting Officer | M | 1,540 | $0.00 | $0.00 |
| Feb 24, 2026 | Colangelo Dominick | President and CEO | M | 18,250 | $0.00 | $0.00 |
| Feb 24, 2026 | Hopper Jonathan Mark | Chief Medical Officer | M | 350 | $0.00 | $0.00 |
| Feb 24, 2026 | Flynn Sean C. | Chief Legal Officer | M | 3,500 | $0.00 | $0.00 |
8 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 4.6/10.
NEUTRAL
144
2/10
Jonathan M. Hopper, an officer of Vericel Corp, filed a Form 144 on June 2, 2026, indicating intent
Jun 2, 2026
NEUTRAL
CLUSTER
2/10
Vericel Corp insiders sold ~$459K in open-market transactions over the past week, representing a tri
May 15, 2026
BULLISH
8-K
7/10
Vericel reported Q1 2026 total revenue of $68.4M (+30% YoY), beating the $63.6M consensus, and a GAA
May 7, 2026
BULLISH
PRESS-RELEASE
8/10
Vericel reported Q1 2026 revenue of $68.4M (+30% YoY) and GAAP EPS of -$0.12 (vs consensus -$0.16, a
May 7, 2026
NEUTRAL
PRESS-RELEASE
3/10
Vericel Corporation announced it will report Q1 2026 financial results on May 7, 2026, with a confer
Apr 23, 2026
NEUTRAL
DEFA14A
3/10
Vericel Corp (VCEL) filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting of Shar
Mar 19, 2026
NEUTRAL
CLUSTER
4/10
Two Vericel Corp executives — the Chief Legal Officer and Chief Operating Officer — sold shares in t
Mar 4, 2026
BULLISH
8-K
8/10
Vericel Corp reported strong Q4 and full-year 2025 financial results with total revenue of $276.3 mi
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 5 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$55.43 mean target
+52.7% upside
Strong Buy (3.00)
$42.00 Low
$70.00 High
| Metric | Value |
|---|---|
| Current Price | $36.30 |
| Target Low | $42.00 |
| Target Mean | $55.43 |
| Target Median | $55.00 |
| Target High | $70.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.04 | $-0.06 | $-0.01 | -250.0% | -333.3% | — | $0.1B | 14.9% | 4 |
| Next Q 2026-09-30 |
$0.09 | $0.04 | $0.12 | -15.0% | +18.6% | 1↑ 0↓ | $0.1B | 17.7% | 4 |
| Current FY 2026-12-31 |
$0.45 | $0.34 | $0.56 | 41.3% | +4.7% | 1↑ 0↓ | $0.3B | 20.3% | 5 |
| Next FY 2027-12-31 |
$0.85 | $0.73 | $1.02 | 88.5% | +5.8% | 1↑ 0↓ | $0.4B | 17.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.035 | |
| 7d ago | $0.015 | -0.050 |
| 30d ago | $0.015 | -0.050 |
| 60d ago | $0.016 | -0.051 |
| 90d ago | $0.092 | -0.128 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 8, 2026
short_volume
Short Volume: VCEL — 57.8% short (0.3M / 0.5M)
Short: 294,683 | Exempt: 0 | TRF Vol: 509,424 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
<p align="center"><strong>Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%</strong></
May 7, 2026
earnings_calendar
VCEL Q1 2026 Earnings Scheduled — 2026-05-07
Apr 23, 2026
earnings
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
<p>CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine an
Apr 2, 2026
contract
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
<p>CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine an
Apr 1, 2026
government_contract
$35M govt contract: VERICEL CORPORATION
Agency: Department of Health and Human Services. NON SURGICAL DEBRIDEMENT
Mar 25, 2026
short_volume
Short Volume: VCEL — 83.8% short (0.6M / 0.7M)
Short: 608,139 | Exempt: 0 | TRF Vol: 725,728 | Short Ratio: 83.8% | Off-exchange volume (dark pool + OTC)
Mar 3, 2026
other
Vericel to Present at Multiple Upcoming Investor Conferences
<p>CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine an
Feb 26, 2026
earnings_calendar
VCEL Q4 2025 Earnings Before Market Open — 2026-02-26